Your Product

Your Product

Back to main menu

Your Product

Services tailored to your product, ensuring the right development path, scalable processes, and consistent manufacturing outcomes.

Learn more
Your Stage

Your Stage

Back to main menu

Your Stage

At each stage, new challenges emerge. A single team and site ensure continuity and consistent execution across the product lifecycle.

Learn more
Our Services

Our Services

Back to main menu

Our Services

Integrated CDMO services designed for seamless progression from development through commercial manufacturing, under global regulatory standards.

Learn more
Resources

Resources

Back to main menu

Resources

Technical insights, practical guidance, and applied expertise to support decision‑making at every stage.

See all resources
About Us

About Us

Back to main menu

About Us

An overview of Groupe PARIMA, our mission, and our expertise in supporting the pharmaceutical industry.

Learn more
    En
    English
    Contact us

    Semi-Solids

    Groupe PARIMA develops and manufactures semi‑solid drug products.

    semi-solids-banner
    SEMI-SOLID DEVELOPMENT AND MANUFACTURING

    CONSISTENT PERFORMANCE AT EVERY SCALE

    Semi-solid drug products require careful control of formulation composition, process parameters, and product attributes to maintain consistent performance through scale-up and commercial manufacturing. Groupe PARIMA combines process understanding, fit-for-purpose analytical methods, and disciplined GMP execution to support robust and reproducible manufacturing.

    Talk to our team

    Performance that holds at scale

    Consistency at scale depends on controlling the process conditions that define semi‑solid performance. We combine process understanding, targeted analytical support, and disciplined documentation to support scale-up, validation, and reliable commercial manufacturing.

    CONSISTENT PERFORMANCE AT SCALE

    We define and control process parameters during scale-up that influence rheology, uniformity, and other critical product attributes.

    LIFECYCLE CONTROL STRATEGY

    Using QbD principles, we establish control strategies based on product and process understanding to support consistent performance throughout the product lifecycle.

    IN‑VITRO RELEASE TESTING

    IVRT methods using Franz diffusion and enhancer cells to assess performance and comparability.

    Scalable processes by design

    We use QbD from the start to define CQAs, identify CPPs affecting viscosity, uniformity, and API release, and build a scalable process supported by the right documentation.

    Formulation Robustness

    We assess formulation robustness that includes product–packaging compatibility studies to identify potential interactions that may affect product stability or performance. We also support extractables and leachables studies where required.

    Critical Quality Attributes

    We ranslate target product profile into CQAs that matter most for semi-solids, such as consistency, uniformity, stability, and performance-relevant characteristics.

    Critical Process Parameters

    Our team identifies process parameters that influence viscosity behavior, uniformity, and API release, with specific attention to mixing and filling conditions.

    Consistency across the lifecycle

    Groupe PARIMA applies control strategies to maintain consistent semi‑solid process and product performance throughout the lifecycle and support process validation and routine production.

    Establish a scalable process

    We define a reproducible process suitable for clinical, exhibit, and commercial production, supported by fit-for-purpose analytical methods aligned with semi-solid scale-up.

    Dosage Form capabilities

    Groupe PARIMA applies dosage-form-specific development and manufacturing capabilities to keep critical attributes consistent as scale-up, equipment, and demand evolve.

    cream
    Cream

    We develop oil-in-water and water-in-oil creams using high-shear homogenization, validated for viscosity, droplet size, and phase stability across shelf life.

    • Emulsion stability under temperature cycling.
    • Homogeneous distribution of poorly soluble APIs.
    • Optimization of pH and preservative systems for microbial protection.
    ointment
    Ointment

    We develop ointments with controlled API solubilization or dispersion and consistent texture and in vitro permeation testing as needed.

    • Choose the right oleaginous or absorption base.
    • Resolve issues with API sedimentation or crystallization.
    • Minimize grittiness and ensure consistent texture and application profile.
    lotion
    Lotion

    We develop lotions with controlled flow properties and stable emulsions, using a scale-ready approach that maintains uniformity through optimized mixing, shear, and cooling profiles.

    • Enhance spreadability without compromising API stability.
    • Select non-irritant emulsifiers and humectants for sensitive applications.
    • Ensure physical stability and microbial robustness in low-viscosity systems.
    gel
    Gel

    We develop gels with highly sensitive to formulation conditions such as polymer level and pH, which is why control matters early. Our team applies IVRT to support formulation optimization and strengthen decision-making.

    • Select gelling agents based on viscosity and drug release.
    • Resolve API-polymer interactions that may impact clarity or stability.
    • Ensure batch-to-batch rheological consistency using detailed viscosity and texture analysis.

    We ensure semi-solid shelf life by controlling key risk drivers from day one, tightening process controls, and confirming performance through fit-for-purpose stability studies.

    Resources

    Access practical guidance on semi-solid development and manufacturing that affects shelf life.

    White papers
    2026/07/06
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    White papers
    2026/07/03
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Blog
    2026/07/03
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more
    White papers
    2026/07/06
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    White papers
    2026/07/03
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Blog
    2026/07/03
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more

    See all Resources

    Contact Us

    De-risk your semi-solid products.

    Tell us about your dosage form and current stage, and discuss shelf-life drivers, process controls, and a practical path to consistent manufacturing.